Polymorphisms of TP53 codon 72 with prostate carcinoma risk: A meta-analysis

Medical Oncology

Volumn 27, Issue 2, 2010, Pages 540-546

  Zhang, Jing ^a   Zhuo, Wen Lei ^a   Zheng, Ying ^a,b   Zhang, Yun Song ^c  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b Physical Examination Group   (China)

^c Chinese PLA 254 Hospital   (China)

Author keywords

Meta analysis; Polymorphism; Prostate carcinoma; Susceptibility; TP53 codon 72

Indexed keywords

PROTEIN P53;

ARTICLE; ASIAN; CANCER RISK; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; CAUCASIAN; CODON; ETHNICITY; GENETIC POLYMORPHISM; HUMAN; MALE; META ANALYSIS; METASTASIS; PRIORITY JOURNAL; PROSTATE CARCINOMA; TUMOR DIFFERENTIATION;

ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; CODON; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROSTATIC NEOPLASMS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77956896286     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-009-9245-5     Document Type: Article

References (39)

1. Fitzpatrick JM, Schulman C, Zlotta AR, et al. Prostate cancer: a serious disease suitable for prevention. BJU Int. 2009;103(7): 864-70. doi:10.1111/j.1464-410X.2008.08206.x.
2. Hiatt RA, Armstrong MA, Klatsky AL, et al. Alcohol consumption, smoking, and other risk factors and prostate cancer in a large health plan cohort in California (United States). Cancer Causes Control. 1994;5(1):66-72. doi:10.1007/BF01830728.
3. Schwartz GG. Vitamin D and intervention trials in prostate cancer: from theory to therapy. Ann Epidemiol. 2009;19(2): 96-102. doi:10.1016/j.annepidem. 2008.03.007.
4. Lesko SM, Rosenberg L, Shapiro S. Family history and prostate cancer risk. Am J Epidemiol. 1996;144(11):1041-7.
5. Li H, Tai BC. RNASEL gene polymorphisms and the risk of prostate cancer: a meta-analysis. Clin Cancer Res. 2006;12(19): 5713-9. doi:10.1158/1078-0432. CCR-05-2799. (Pubitemid 44629600)
6. Wang GY, Lu CQ, Zhang RM, et al. The E-cadherin gene polymorphism 160C->A and cancer risk: a HuGE review and meta-analysis of 26 case-control studies. Am J Epidemiol. 2008;167(1):7-14. doi:10.1093/aje/kwm264.
7. Mo Z, Gao Y, Cao Y, et al. An updating meta-analysis of the GSTM1, GSTT1, and GSTP1 polymorphisms and prostate cancer: a HuGE review. Prostate. 2009;69(6):662-88. doi:10.1002/ pros.20907.
8. Bai JL, Zheng MH, Xia X, et al. MTHFR C677T polymorphism contributes to prostate cancer risk among Caucasians: a metaanalysis of 3511 cases and 2762 controls. Eur J Cancer. 2009; doi:10.1016/j.ejca.2009.01.020.
9. Ntais C, Polycarpou A, Ioannidis JP. Association of the CYP17 gene polymorphism with the risk of prostate cancer: a metaanalysis. Cancer Epidemiol Biomarkers Prev. 2003;12(2): 120-6.
10. Severi G, Giles GG, Southey MC, et al. ELAC2/HPC2 polymorphisms, prostate-specific antigen levels, and prostate cancer. J Natl Cancer Inst. 2003;95(11):818-24.
11. Ntais C, Polycarpou A, Ioannidis JP. Vitamin D receptor gene polymorphisms and risk of prostate cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2003;12(12):1395-402. (Pubitemid 38031740)
12. Bumroongkit K, Rannala B, Traisathit P, et al. TP53 gene mutations of lung cancer patients in upper northern Thailand and environmental risk factors. Cancer Genet Cytogenet. 2008;185: 20-7. doi:10.1016/j.cancergencyto.2008.04.009. (Pubitemid 352010359)
13. Assumpcao JG, Seidinger AL, Mastellaro MJ, et al. Association of the germline TP53 R337H mutation with breast cancer in southern Brazil. BMC Cancer. 2008;8:357. doi:10.1186/1471-2407-8-357.
14. Mahdavinia M, Bishehsari F, Verginelli F, et al. P53 mutations in colorectal cancer from northern Iran: relationships with site of tumor origin, microsatellite instability and K-ras mutations. J Cell Physiol. 2008;216:543-50. doi:10.1002/jcp.21428. (Pubitemid 351898483)
15. Ara S, Lee PS, Hansen MF, et al. Codon 72 polymorphism of the TP53 gene. Nucleic Acids Res. 1990;18:4961. doi:10.1093/nar/ 18.16.4961.
16. Shen H, Solari A, Wang X, et al. P53 codon 72 polymorphism and risk of gastric cancer in a Chinese population. Oncol Rep. 2004;11:1115-20.
17. Storey A, Thomas M, Kalita A, et al. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature. 1998;393:229-34. doi:10.1038/30400. (Pubitemid 28261713)
18. Wang YC, Lee HS, Chen SK, et al. Prognostic significance of p53 codon 72 polymorphism in lung carcinomas. Eur J Cancer. 1999;35:226-30. doi:10.1016/S0959-8049(98)00369-4. (Pubitemid 29136772)
19. Yu MW, Yang SY, Chiu YH, et al. A p53 genetic polymorphism as a modulator of hepatocellular carcinoma risk in relation to chronic liver disease, familial tendency, and cigarette smoking in hepatitis B carriers. Hepatology. 1999;29:697-702. doi:10.1002/ hep.510290330.
20. Mabrouk I, Baccouche S, El-Abed R, et al. No evidence of correlation between p53 codon 72 polymorphism and risk of bladder or breast carcinoma in Tunisian patients. Ann N Y Acad Sci. 2003;1010:764-70. doi:10.1196/annals.1299. 137. (Pubitemid 38265078)
21. Munafò MR, Clark TG, Flint J. Assessing publication bias in genetic association studies: evidence from a recent meta-analysis. Psychiatry Res. 2004;129:39-44. doi:10.1016/j.psychres.2004.06.011. (Pubitemid 39574435)
22. Egger M, Davey Smith G, Schneider M, et al. Bias in metaanalysis detected by a simple, graphical test. BMJ. 1997;315: 629-34.
23. Huang SP, Huang CY, Wang JS, et al. Prognostic significance of p53 and X-ray repair cross-complementing group 1 polymorphisms on prostate-specific antigen recurrence in prostate cancer post radical prostatectomy. Clin Cancer Res. 2007;13(22 Pt 1):6632-8. doi:10.1158/1078-0432.CCR-07-1437. (Pubitemid 350206798)
24. Wu WJ, Kakehi Y, Habuchi T, et al. Allelic frequency of p53 gene codon 72 polymorphism in urologic cancers. Jpn J Cancer Res. 1995;86(8):730-6.
25. Henner WD, Evans AJ, Hough KM, et al. Association of codon 72 polymorphism of p53 with lower prostate cancer risk. Prostate. 2001;49(4):263-6. doi:10.1002/pros.10021. (Pubitemid 33117001)
26. Suzuki K, Matsui H, Ohtake N, et al. A p53 codon 72 polymorphism associated with prostate cancer development and progression in Japanese. J Biomed Sci. 2003;10(4):430-5. doi: 10.1007/BF02256434.
27. Wu HC, Chang CH, Chen HY, et al. p53 gene codon 72 polymorphism but not tumor necrosis factor-alpha gene is associated with prostate cancer. Urol Int. 2004;73(1):41-6. doi:10.1159/00 0078803.
28. Huang SP, Wu WJ, Chang WS, et al. p53 Codon 72 and p21 codon 31 polymorphisms in prostate cancer. Cancer Epidemiol Biomarkers Prev. 2004;13(12):2217-24.
29. Leiros GJ, Galliano SR, Sember ME, et al. Detection of human papillomavirus DNA and p53 codon 72 polymorphism in prostate carcinomas of patients from Argentina. BMC Urol. 2005;5:15. doi:10.1186/1471-2490-5-15. (Pubitemid 41803094)
30. Tobias A. Assessing the influence of a single study in the metaanalysis estimate. Stata Tech Bull. 1999;8:15-7.
31. Koushik A, Platt RW, Franco EL. p53 codon 72 polymorphism and cervical neoplasia: a meta-analysis review. Cancer Epidemiol Biomarkers Prev. 2004;13:11-22. doi:10.1158/1055-9965.EPI-083-3. (Pubitemid 38116615)
32. Jee SH, Won SY, Yun JE, et al. Polymorphism p53 codon-72 and invasive cervical cancer: a meta-analysis. Int J Gynaecol Obstet. 2004;85:301-8. doi:10.1016/j.ijgo.2003.08.017. (Pubitemid 38622573)
33. Sousa H, Santos AM, Pinto D, et al. Is the p53 codon 72 polymorphism a key biomarker for cervical cancer development? A meta-analysis review within European populations. Int J Mol Med. 2007;20:731-41.
34. Zhou Y, Li N, Zhuang W, et al. P53 codon 72 polymorphism and gastric cancer: a meta-analysis of the literature. Int J Cancer. 2007;121:1481-6. doi:10.1002/ijc.22833. (Pubitemid 47328706)
35. Matakidou A, Eisen T, Houlston RS. TP53 polymorphisms and lung cancer risk: a systematic review and meta-analysis. Mutagenesis. 2003;18:377-85. doi:10.1093/mutage/geg008. (Pubitemid 36850206)
36. Li Y, Qiu LX, Shen XK, et al. A meta-analysis of TP53 codon 72 polymorphism and lung cancer risk: evidence from 15,857 subjects. Lung Cancer. 2009; doi:10.1016/j.lungcan.2008.12.009.
37. Pietsch EC, Humbey O, Murphy ME. Polymorphisms in the p53 pathway. Oncogene. 2006;25:1602-11. doi:10.1038/sj.onc.1209 367.
38. Dumont P, Leu JI, Della Pietra AC III, et al. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet. 2003;33:357-65. doi:10.1038/ng1093. (Pubitemid 36278852)
39. Chang CC, Hsieh YY, Tsai FJ, et al. The proline form of p53 codon 72 polymorphism is associated with endometriosis. Fertil Steril. 2002;77:43-5. doi:10.1016/S0015-0282(01)02938-7. (Pubitemid 34093891)